14
Sun, Apr
46 New Articles

PRK Partners Advises Affimed on Divestment of AbCheck

PRK Partners Advises Affimed on Divestment of AbCheck

Czech Republic
Tools
Typography
  • Smaller Small Medium Big Bigger
  • Default Helvetica Segoe Georgia Times

PRK Partners has advised Affimed on its successful divestment of AbCheck to Flagship Pioneering company Ampersand Biomedicines.

Affimed is a clinical-stage immuno-oncology company.

AbCheck is a Czech biotechnology company focusing on the discovery and development of human therapeutic antibodies.

According to PRK Partners, “through the transaction, AbCheck became a wholly-owned subsidiary of Ampersand Biomedicines, a Flagship Pioneering company.”

The PRK Partners team included Partner Monika Maskova and Co-Head of Corporate and M&A Milan Sivy.

PRK Partners did not respond to our inquiry on the matter.

Our Latest Issue